STAAR Surgical Gains Regulatory Approval in India for Its Visian® ICL™ with CentraFLOW™

 STAAR Surgical Gains Regulatory Approval in India for Its Visian® ICL™ with

~ Growing Number of Approvals for CentraFLOW Technology Driving Increased
Adoption of ICL Procedure

~~Marketing Launch at Two Major Meetings in India

PR Newswire

MONROVIA, Calif., Aug. 19, 2013

MONROVIA, Calif., Aug. 19, 2013 /PRNewswire/ -- STAAR Surgical Company
(NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable
lenses and delivery systems for the eye, today announced that it has received
regulatory approval to market its Visian® Implantable Collamer® Lens (ICL™)
with CentraFLOW™ technology from the CDSCO in India.

"Following our recent approval in Korea, we are delighted to add India to the
growing list of markets in which we now have the CentraFLOW technology to help
drive market share growth in the Asia Pacific region," said Don Todd,
President of the Asia Pacific Region for STAAR Surgical. "During the first
half of this year, the Visian ICL with CentraFLOW contributed to the 54%
growth in European markets. During the past four years, the Compound Annual
Growth Rate (CAGR) for the Visian ICL has been 48% in India. Our marketing
partner, Spica Medical, has seen a lot of anticipation in the market for the
CentraFLOW technology as inquiries from surgeons and clinics over the past few
weeks have been tremendous. With this approval in India, we can now leverage
this growing acceptance to further penetrate a significantly large market."

Several key refractive surgeons in India have expressed their excitement about
the new technology. Dr. Sri Ganesh, Chairman and Managing Director of
Nethradhama Hospital, said, "STAAR has just made an excellent product better.
The Visian ICL with CentraFLOW is a very innovative design which improves
patient safety and efficiency for the surgeon. The patient experience now with
the Visian ICL CentraFLOW technology will be as good as or even better than

Dr. Kasu Prasad Reddy, founder of Maxivision Eye Hospitals who has conducted
over 45,000 refractive procedures, added, "A little hole in the Visian ICL
optic, which eliminates a surgical peripheral iridotomy procedure, is a
brilliant step towards surgical ease and patient comfort."

According to a Market Scope 2013 Comprehensive Report on The Global Refractive
Surgery Market, India has a population of approximately 1.2 billion and
approximately 149,000 refractive procedures were performed last year. The
demand for refractive surgery in India is lower than other markets based upon
a couple of key factors which make the Visian ICL procedure an attractive
option. The investments required to purchase and maintain an excimer laser
are high and there are documented studies that the population of India
generally has thinner corneas making LASIK a more challenging procedure for
treatment. The Market Scope estimate for 2012 is that overall refractive
procedures grew 5% while the Visian ICL grew 26%. The Company believes the
Visian ICL has over a 4% market share of all refractive procedures in India.

The Visian ICL CentraFLOW technology was launched from a marketing perspective
at two major meetings in India during the past few weeks. The first meeting
was the Intraocular Implant and Refractive Society, India (IIRSI) meeting
which was held on July 6 and 7 in Chennai, India. During the Congress meeting
on July 6^th, Dr. M. Alaa El Danasoury, Chief Medical Officer at Magrabi
Hospitals and past President of the International Society of Refractive
Surgery, performed live bilateral toric surgery utilizing the Visian ICL
CentraFLOW technology. On July 7^th,a Visian ICL User's Meeting was held with
leading ICL surgeons including: Dr. Alaa, Dr. Ganesh, Dr. Paul (Butch) Harton
from the U.S., and Dr. Rajesh Fogla and Dr. Matthew Kurian from India. The
Moderators for the Visian User's Meeting were Dr. Partha Biswas and Dr. Anand
Parthsarathy, both from India.

The IIRSI meeting attracted a record attendance of approximately 1,500
ophthalmologists to Chennai. The India Minister of Health, K.C. Veeranani,
spoke to the delegates about the state government's high priority for eye
care. During this Inauguration Session, STAAR CEO, Barry G. Caldwell and
President of Asia/Pacific, Don Todd, presented Dr. Amar Agarwal, Secretary
General of the IIRSI, a model of an enlarged Visian ICL with CentraFLOW
technology which was designed for the presentation. Dr. Agarwal then gave the
model to the Minister of Health representing the official launch of the
CentraFLOW technology to India.

The second major meeting was the XXI Annual Conference of the Bombay
Ophthalmologists Association, August 2-4, in Mumbai. Over 1,400 delegates
registered for the Conference. During this Conference, on August 2, Dr. Sri
Ganesh performed live surgery with the Visian ICL CentraFLOW to demonstrate
the features and benefits of the technology to the audience. In addition,
there was a dedicated Visian ICL session at the Conference on August 3. The
speakers and moderators of the ICL session were leading surgeons from around
India. Presenting at the session were Dr. Sri Ganesh, Dr. Keiki Mehta, Dr.
Anand Parthasarath, Dr. D. Ramamurthy, and Dr. Purendra Bhasin. The
moderators were Dr. Anand Shroff and Dr. Partha Biswas.

The CentraFLOW™ technology utilizes the KS-AquaPORT™, or KS-AP™, in the center
of the ICL optic, to optimize the flow of fluid within the eye. This
proprietary technology eliminates the need for the surgeon to perform a YAG
peripheral iridotomy procedure days before the ICL implant, thus eliminating
an additional procedure and office visit. This results in more comfort for
the patient and a more convenient, efficient ICL experience for both the
patient and the surgeon. The Visian ICL, which is currently the fastest
growing refractive technology, has demonstrated an even greater growth rate
with this enhancement. Nearly 25,000 implants of the Visian CentraFLOW
technology have been successfully performed in Europe.

This approval expands the market opportunity for the Visian ICL as the range
of refractive errors treatable has significantly increased. The expanded range
for the Visian ICL with CentraFLOW will now go from -0.5 diopter to -18.0
diopters on the myopic range and +0.5 cylinder power to +6.0 for the Toric ICL

About STAAR Surgical

STAAR, which has been dedicated solely to ophthalmic surgery for over 25
years, designs, develops, manufactures and markets implantable lenses for the
eye and delivery systems therefor. All of these lenses are foldable, which
permits the surgeon to insert them through a small incision. STAAR's lens used
in refractive surgery as an alternative to LASIK is called an Implantable
Collamer® Lens or "ICL." A lens used to replace the natural lens after
cataract surgery is called an intraocular lens or "IOL." Over 375,000 Visian
ICLs have been implanted to date; to learn more about the ICL go to: STAAR has approximately 300 full time employees and
markets lenses in over 60 countries. Headquartered in Monrovia, CA, it
manufactures in the following locations: Nidau, Switzerland; Aliso Viejo, CA;
and Monrovia, CA. For more information, please visit the Company's website at

Safe Harbor

All statements in this press release that are not statements of historical
fact are forward-looking statements, including any statements about the effect
of new product approvals on our business, market size, product performance, or
product acceptance, any statements of belief and any statements of assumptions
underlying any of the foregoing. Important additional factors that could
cause actual results to differ materially from those indicated by such
forward-looking statements are set forth in the company's Annual Report on
Form 10-K for the year ended December 28, 2012, under the caption "Risk
Factors," which is on file with the Securities and Exchange Commission and
available in the "Investor Information" section of the company's website under
the heading "SEC Filings."

These statements are based on expectations and assumptions as of the date of
this press release and are subject to numerous risks and uncertainties, which
could cause actual results to differ materially from those described in the
forward-looking statements. The risks and uncertainties include the following:
our need to compete against much larger and better financed companies in
selling refractive surgical procedures; our limited resources to promote new
products and the risk that product launches may be affected by unplanned
delays or be less successful than we anticipate; the effect of the global
recession on sales of products, especially products such as the ICL used in
non-reimbursed elective procedures, the entrenched position of laser-based
refractive surgical procedures in many markets, and the willingness of
surgeons and patients to adopt a new product and procedure. STAAR assumes no
obligation to update its forward-looking statements to reflect future events
or actual outcomes and does not intend to do so.

CONTACT: Investors         Media
         EVC Group               EVC Group
         Doug Sherk, 415-652-9100 Janine McCargo
         Leigh Salvo, 415-568-9348 646-688-0425

SOURCE STAAR Surgical Company

Press spacebar to pause and continue. Press esc to stop.